Shalby Ltd (SHALBY) — shareholding pattern, promoter holding, financials and share price

About Shalby Ltd (SHALBY)

Shalby Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as SHALBY and on the BSE under scrip code 540797. Its ISIN is INE597J01018.

Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc. [1] The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.

Shalby Limited is an Ahmedabad‑headquartered integrated healthcare group operating 15 hospitals with 2,300+ beds across India and a growing implant MedTech vertical, combining multi‑specialty hospital services and an in‑house implant manufacturing and distribution platform (SAT, SMT, SGT). The company also operates international OPDs and owns an implant facility in California.

Q3 FY26 consolidated revenue was INR 2,794 million (down 0.6% YoY) with consolidated EBITDA of INR 375 million and consolidated net debt of INR 4,086 million; standalone hospital EBITDA and PBT declined materially QoQ and YoY, highlighting near‑term margin pressure at hospital operations despite steady ARPOB and improving PAT. Annualized ROCE stands at 6.7% consolidated.

Listed peers in Hospital: Dr Agarwals Eye Hospital Ltd, KMC Speciality Hospitals (India) Ltd, Unihealth Hospitals Ltd, GPT Healthcare Ltd, Gujarat Kidney & Super Speciality Ltd, KRM Ayurveda Ltd.

Valuation & Returns

10 Jul 2026

At ₹171.25 a share on 10 Jul 2026, Shalby Ltd (SHALBY) was valued at a price-to-earnings ratio of 53.32x against an industry P/E of 61.73x and a price-to-book of 1.86x on a book value of ₹91.86 per share as of Mar 2025. Solomo computes return on equity of 3.5% and return on capital employed of 6.78% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
53.32x
Industry P/E
61.73x
P/B
1.86x
EPS (TTM)
₹3.21
Book value / share
₹91.86
ROE
3.5%
ROCE
6.78%
ROA
2.04%
Debt / equity
0.48x
Dividend yield
0%
EBITDA margin
14.85%
52-week range
₹125.7 – ₹274.5

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Shalby Ltd (SHALBY) reported revenue of ₹1,141 crore, net profit of ₹35 crore and earnings per share of ₹3.46. That compares with revenue of ₹1,087 crore and net profit of ₹2 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹287 crore and net profit ₹18 crore (consolidated).

Consolidated annual results for Shalby Ltd (SHALBY), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)6998059341,0871,141
Net profit (₹ cr)546884235
EPS (₹)5.016.277.780.583.46
Compound annual growth for Shalby Ltd (SHALBY). Stock price CAGR is price return and excludes dividends.
Measure10Y5Y3Y1Y
Sales growth13.20%12.52%10.50%16.41%
Profit growth12.22%24.54%6.28%-97.70%
Stock price CAGR--3%-4%-16%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 74.33% of Shalby Ltd (SHALBY) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.46% and domestic institutional investors (DII) hold 0.3%. Market capitalisation was ₹1,850 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2017.

Largest disclosed public shareholders in Jun 2026: FIRST WATER FUND 1.73%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202674.33%-4.46%0.3%25.02%
Mar 202674.33%-4.36%0.25%25.02%
Dec 202574.33%-4.47%0.2%25.01%
Sep 202574.33%-4.64%0.2%25.01%
Jun 202574.27%-5.2%0.2%25.04%
Mar 202574.27%-4.54%0.18%25.04%
Dec 202474.27%-4.65%0.14%25.04%
Sep 202474.25%-5.37%0.09%25.06%
Every quarter since Dec 2017 Filing data, not investment advice.